{"id":"NCT02582814","sponsor":"AstraZeneca","briefTitle":"The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM","officialTitle":"A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-26","primaryCompletion":"2017-06-15","completion":"2017-06-15","firstPosted":"2015-10-21","resultsPosted":"2019-04-12","lastUpdate":"2019-04-12"},"enrollment":151,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dapagliflozin 5 mg","otherNames":[]},{"type":"DRUG","name":"Dapagliflozin 10mg","otherNames":[]}],"arms":[{"label":"dapagliflozin 5mg + insulin","type":"EXPERIMENTAL"},{"label":"dapagliflozin 10mg + insulin","type":"EXPERIMENTAL"}],"summary":"This study will enroll eligible subjects into a long-term safety study (Part B).\n\nJapanese male and female patients with T1DM and age 18 to 75 years, with inadequate glycemic control on insulin defined as HbA1c ≥ 7.5% and ≤ 10.5% at screening visit. As a condition of enrollment, subjects must be on a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to the screening visit. The study design of Part B is a randomized, open-label, 2 arm, parallel-group design. 140 Japanese subjects in total will be randomized in a 1:1 ratio into one of the two treatment arms; dapagliflozin 5 mg or dapagliflozin 10 mg.","primaryOutcome":{"measure":"Overall Adverse Event Summary","timeFrame":"From baseline to 52 weeks","effectByArm":[{"arm":"Dapagliflozin 5mg + Insulin","deltaMin":67,"sd":null},{"arm":"Dapagliflozin 10mg + Insulin","deltaMin":55,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":24,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3797&filename=D1695C00001_SAP_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3797&filename=D1695C00001_CSP_redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":76},"commonTop":["NASOPHARYNGITIS","GASTROENTERITIS","PHARYNGITIS","POLLAKIURIA","KETOSIS"]}}